ClinicalTrials.gg

Program

cariprazine

Also written as “Cariprazine”, “MP-214 3mg” and “MP-214 6mg”.

Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Bipolar Disorder · Mania · Depression, led by 7 companies.

Furthest: phase 3, since Jan 27, 201041 company-led studies, 4 open or runningNext primary completion: Dec 15, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie291 open or runningphase 3since Jan 27, 2010Nov 27, 2006Mar 2027phase 3 · NCT04777357
Tanabe Pharma60 open or runningphase 3since Jun 19, 2012Mar 15, 2009none ahead
Gedeon Richter Plc.21 open or runningphase 3since Jan 24, 2019Jun 13, 2014Dec 15, 2026phase 3 · NCT03817502
Bostal Drug Delivery11 open or runningphase 3since Jul 15, 2026Jul 15, 2026Aug 2027phase 3 · NCT07722728
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Jul 1, 2026Jul 1, 2026none ahead
Mapi Pharma11 open or runningphase 2since Aug 28, 2025Aug 28, 2025Dec 31, 2026phase 2 · NCT07185815
Whanin Pharmaceutical10 open or runningphase 3since Nov 26, 2021Nov 26, 2021none ahead

Also a collaborator on its studies: gedeon-richter-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 25 studies since Nov 27, 2006.

  1. Jan 28, 20162 phase 3 studies in Bipolar DisorderAbbVie · NCT02670551, NCT02670538
  2. Jun 5, 2018Phase 3 study in ManiaAbbVie · NCT03573297 · 901 enrolled · United States, Bulgaria, Korea, Republic of and more
  3. Jul 10, 2018Phase 3 study in SchizophreniaAbbVie · NCT03593213 · 587 enrolled · United States, Bulgaria, Korea, Republic of and more
  4. Nov 8, 20182 phase 3 studies in Depressive Disorder, MajorAbbVie · NCT03738215, NCT03739203
  5. Jan 24, 2019Phase 3 study in SchizophreniaGedeon Richter Plc. · NCT03817502 · 330 planned · United States, Bulgaria, Colombia and more
  6. Mar 19, 2020Phase 1 study in Autism Spectrum DisorderAbbVie · NCT04382885 · 24 enrolled · United States
  7. Feb 26, 2021Phase 3 study in DepressionAbbVie · NCT04777357 · 380 planned · United States, Puerto Rico, Russia
  8. Jul 7, 2021Phase 2 study in Generalized Anxiety DisorderAbbVie · NCT04965272 · United States
  9. Nov 26, 2021Whanin Pharmaceutical's first study: phase 3 study in SchizophreniaNew to Whanin PharmaceuticalWhanin Pharmaceutical · NCT05168007 · 342 enrolled · Korea, Republic of
  10. May 6, 2022Phase 3 study in SchizophreniaAbbVie · NCT05368558 · 34 enrolled · Japan, Taiwan
  11. Jun 28, 2022Phase 3 study in Autism Spectrum DisorderAbbVie · NCT05439616 · 161 enrolled · United States, Puerto Rico
  12. Aug 28, 2025Mapi Pharma's first study: phase 2 study in SchizophreniaNew to Mapi PharmaMapi Pharma · NCT07185815 · 24 planned · India, Israel
  13. Jul 1, 2026Humanis Saglık Anonim Sirketi's first study: phase 1 study in SCHIZOPHRENIA 1 (Disorder)New to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07691190 · 32 enrolled · India
  14. Jul 15, 2026Bostal Drug Delivery's first study: phase 3 study in SchizophreniaNew to Bostal Drug DeliveryBostal Drug Delivery · NCT07722728 · 84 planned

Ahead

  1. Dec 15, 2026Primary completion: phase 3 study in SchizophreniaGedeon Richter Plc. · NCT03817502
  2. Dec 31, 2026Primary completion: phase 2 study in SchizophreniaMapi Pharma · NCT07185815
  3. Mar 2027Primary completion: phase 3 study in DepressionAbbVie · NCT04777357
  4. Aug 2027Primary completion: phase 3 study in SchizophreniaBostal Drug Delivery · NCT07722728

TargetBeta

DRD2 →DRD3 →read by rule
“Dopamine D3 receptor modulator; Dopamine D2 receptor modulator”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
OlanzapineruleEli Lillyphase 476
rotigotineruleUCBphase 464
PramipexoleruleBoehringer Ingelheimphase 444
ABBV-932AbbViephase 210

Studies

All 41 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07722728Schizophrenia3Not yet recruitingBostal Drug DeliveryAug 202784
NCT07691190SCHIZOPHRENIA 1 (Disorder) · India1CompletedHumanis Saglık Anonim SirketiJun 2, 202632
NCT07185815Schizophrenia · India, Israel2RecruitingMapi PharmaDec 31, 202624
NCT05439616Autism Spectrum Disorder · United States, Puerto Rico3CompletedAbbVieOct 4, 2024161
NCT05368558Schizophrenia · Japan, Taiwan3TerminatedAbbVieSep 20, 202434
NCT05168007Schizophrenia · Korea, Republic of3UNKNOWNWhanin PharmaceuticalJul 17, 2023342
NCT04965272Generalized Anxiety Disorder · United States2WithdrawnAbbVieAug 24, 20210
NCT04777357Depression · United States, Puerto Rico, Russia3RecruitingAbbVieMar 2027380
NCT04382885Autism Spectrum Disorder · United States1CompletedAbbVieDec 10, 202124
NCT03817502Schizophrenia · United States, Bulgaria, Colombia and more3RecruitingGedeon Richter Plc.Dec 15, 2026330
NCT03739203Depressive Disorder, Major · United States, Canada, Czechia and more3CompletedAbbVieSep 6, 2021752
NCT03738215Depressive Disorder, Major · United States, Bulgaria, Estonia and more3CompletedAbbVieSep 30, 2021759
NCT03593213Schizophrenia · United States, Bulgaria, Korea, Republic of and more3TerminatedAbbVieFeb 11, 2021587
NCT03573297Mania · United States, Bulgaria, Korea, Republic of and more3CompletedAbbVieSep 5, 2022901
NCT02670551Bipolar Disorder · United States, Bulgaria, Estonia and more3CompletedAbbVieJul 19, 2017488
NCT02670538Bipolar Disorder · United States, Bulgaria, Croatia and more3CompletedAbbVieJan 18, 2018493
NCT02165098Pharmacokinetic Profile · United Kingdom1CompletedGedeon Richter Plc.Feb 2016160
NCT01838876Depressive Disorder, Major · United States, Puerto Rico3CompletedAbbVieJul 27, 2015442
NCT01715805Depressive Disorder, Major · United States, Puerto Rico3CompletedAbbVieJun 24, 20161,022
NCT01626885Schizophrenia · Japan3CompletedTanabe PharmaJun 201442
NCT01626872Schizophrenia · Japan, South Korea, Taiwan3CompletedTanabe PharmaOct 2016254
NCT01626859Schizophrenia · Japan3CompletedTanabe PharmaAug 201338
NCT01625897Schizophrenia · Japan3CompletedTanabe PharmaMar 2015125
NCT01625000Schizophrenia · Japan, South Korea, Taiwan3CompletedTanabe PharmaAug 2015512
NCT01469377Depressive Disorder, Major · United States, Estonia, Finland and more2CompletedAbbVieDec 12, 2013819
NCT01412060Schizophrenia · United States, India, Romania and more3CompletedAbbVieSep 3, 2014765
NCT01396447Bipolar Disorder · United States, Bulgaria, Canada and more2CompletedAbbVieJan 10, 2014584
NCT01376076Schizophrenia · United States1CompletedAbbVieFeb 2012129
NCT01104779Schizophrenia · United States, Colombia, India and more3CompletedAbbVieDec 15, 2011446
NCT01104792Schizophrenia · United States, Colombia, India and more3CompletedAbbVieJan 31, 2013752
NCT01104766Schizophrenia · United States, Romania, Russian Federation and more3CompletedAbbVieDec 20, 2011617
NCT01059539Mania · United States, Hungary, Poland and more3CompletedAbbVieFeb 29, 2012403
NCT01058668Mania · United States, Croatia, Romania and more3CompletedAbbVieDec 2011497
NCT01058096Bipolar Disorder · United States, India3CompletedAbbVieJul 2011323
NCT00862992Schizophrenia · Japan2CompletedTanabe PharmaSep 200934
NCT00854100Depressive Disorder, Major · United States2CompletedAbbVieDec 6, 2010231
NCT00852202Bipolar Disorder · United States2CompletedAbbVieJun 15, 2010234
NCT00839852Schizophrenia · United States, India, Malaysia and more2CompletedAbbVieAug 31, 201097
NCT00694707Schizophrenia · United States, India, Malaysia and more2CompletedAbbVieAug 31, 2009732
NCT00488618Bipolar Disorder · United States2CompletedAbbVieJul 2008238
NCT00404573Schizophrenia · United States2CompletedAbbVieAug 2007375

How it is read

Names in the registry

  • “Cariprazine”, 25 entries
  • “MP-214 3mg”, 3 entries
  • “MP-214 6mg”, 3 entries
  • “MP-214 9mg”, 3 entries
  • “MP-214”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.